Today Jan 16th the FDA advisory comm will review the CV safety of anti-sclerostin drug Evenity (romosozumab). July 2018 the FDA issued a complete response letter for CV safety concerns. Amgen seeks indication for use in postmenopausal osteoporosis. https://t.co/IRr1nKJ43s